Abstract
The prognosis of patients with advanced biliary tract cancer is poor. Preferred first-line chemotherapy for these patients is a combination of gemcitabine plus cisplatin, following the results of the ABC-02 trial.1 The ABC-06 trial2 compared active symptom control with active symptom control and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) in patients with advanced biliary tract cancer who had progressed on gemcitabine plus cisplatin, and showed improved overall survival with the addition of FOLFOX.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
